SVRA Savara

Savara Announces Participation in Upcoming Healthcare Investor Conferences

LANGHORNE, Pa.--(BUSINESS WIRE)--

(Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending two upcoming healthcare investor conferences and participating in fireside chats at each.

Guggenheim SMID Cap Biotech Conference, February 5-6, 2025

Fireside Chat: February 5th, 10:00am ET/7:00am PT

Oppenheimer 35th Annual Healthcare Life Sciences Conference, February 11-12, 2025

Fireside Chat: February 11th, 8:00am ET/5:00am PT

The live webcasts and subsequent replays will be available on the “Events & Presentations” section of the Company’s corporate website at and will be archived for 90 days.

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at , X: and .

*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication.

EN
29/01/2025

Underlying

SVRASavara

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Savara

 PRESS RELEASE
Free
SVRA SAVARA

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim In...

LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced a manuscript titled, was published online in the journal ERJ Open Research. The outcomes data presented suggest that treatment with molgramostim addresses the underlying pathophysiology of aPAP, resulting in improved lung function, decreased disease burden, restored patient functionality, and reduction of clinical symptoms, and may enable resumption of daily life activities. This case series retrospectively evaluated five aPAP pati...

5h / 33m 1 EN
 PRESS RELEASE
Free
SVRA SAVARA

Savara Announces Participation in Upcoming Healthcare Investor Confere...

LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending two upcoming healthcare investor conferences and participating in fireside chats at each. Guggenheim SMID Cap Biotech Conference, February 5-6, 2025 Fireside Chat: February 5th, 10:00am ET/7:00am PT Oppenheimer 35th Annual Healthcare Life Sciences Conference, February 11-12, 2025 Fireside Chat: February 11th, 8:00am ET/5:00am PT The live webcasts and subsequent replays will be av...

22h / 7m 1 EN
 PRESS RELEASE
Free
SVRA SAVARA

Savara Announces New Employment Inducement Grant

LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On December 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 100,000 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 100,000 shares of the Company’s common stock. These equity...

December 23, 2024 1 EN
 PRESS RELEASE
Free
SVRA SAVARA

Savara Initiates Rolling Submission of a Biologics License Application...

LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, initiated a rolling submission of a BLA to the FDA for MOLBREEVI for the potential treatment of aPAP, a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. MOLBREEVI was granted Fast Track and Breakthrough Therapy Designations in 2019 for the treatment of patients with aPAP. As a result, the Company is allowed to submit individual modules of the BLA as they are completed rather th...

December 18, 2024 1 EN
 PRESS RELEASE
Free
SVRA SAVARA

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthca...

LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference. Date/Time of Presentation: January 15, 5:15pm PT/8:15pm ET Presenter: Matt Pauls, Chair and Chief Executive Officer, Savara Location: Westin St. Francis, San Francisco, Elizabethan C Room The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company’s corporate website at and will...

December 17, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch